CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ROKIT America Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ROKIT America Inc
3435 WILSHIRE Blvd.
Phone: (678) 861-0046p:678 861-0046 LOS ANGELES, CA  90010  United States
Business Summary
ROKIT America, Inc. is an integrated bio-health enterprise which supports cellular health and aging-related biological processes at the molecular level. The Company's artificial intelligence (AI) hyper-personalized organ regeneration platform (ORP) is a proprietary technology which provides regenerative medicine solutions in the Americas. Its flagship product line, ROKIT AMERICA NMN, combines nicotinamide mononucleotide (NMN) with compounds such as pterostilbene to support Nicotinamide Adenine Dinucleotide (NAD) biosynthesis, which supports cellular metabolism, deoxyribonucleic acid (DNA) repair, and energy restoration. The ORP integrates four key proprietary technologies: a three-dimensional (3D) bioprinter designed for clinical use; AI-powered wound modeling for automated and precise scaffold design; proprietary technology to manufacture hyper-personalized bioinks from autologous bioink, and a sterile, single-use regenerative kit enabling standardized procedures.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Chairman of the Board of Director Seok HwanYou 68 1/1/2025 1/1/2025
Chief Financial Officer, Director Ha YoungKim 51 1/1/2025 1/1/2025
Chief Operating Officer Woo YoungKim 32 1/1/2025 1/1/2025
7 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 27,631,679 (As of 3/31/2026)
Federal Tax Id: 384124442


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 20, 2026